Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Ups Ante on Drug Distribution after Fake Harvoni Issue
February 17, 2017
- Council OKs Public Knowledge-Based Applications for Rituxan, Ovisot
February 17, 2017
- MHLW Council Recognizes High Medical Need for 4 APIs/5 Products Including Extended-Release Levodopa/Carbidopa Combo
February 17, 2017
- MHLW Council Discusses Issue of Development Requests for Drugs with Low NHI Prices, Few Patients
February 17, 2017
- With Eye to June Listing, 24 Generic Makers Flock to Micardis Family, 15 to Abilify
February 16, 2017
- Optimal Use Guidelines Issued for Opdivo, Keytruda for Melanoma, NSCLC Use
February 15, 2017
- Label Changes Ordered for Atarax, Zelboraf on New ADRs
February 15, 2017
- MHLW Mulls Administrative Penalties, Tighter Regulations after Counterfeit Harvoni Case
February 14, 2017
- Ex-LDP Health Panel Chief Calls for Changing Copay Rates for Different Drugs
February 13, 2017
- Zoster Vaccine’s Add’l Use, DPT Vaccine’s Booster Dose Put Under Continued Discussion for Public Immunization Program
February 13, 2017
- PMDA Eyes 15-20% New Drug Review Fee Raise in April, Plan Now Up for Public Comments
February 13, 2017
- Japan’s First Guidance for Development of Cancer Immunotherapies Will Promote Development
February 13, 2017
- Drugs Subject to Optimal Use Guidelines Will Be a Rarity: Mori
February 13, 2017
- MHLW Weighs Use of Medical Bill Database for 4 Times Yearly Price Review: Nakayama
February 10, 2017
- MHLW Councilor Cites Cancer Meds for Conditional Early Approval Scheme
February 10, 2017
- MHLW Advisory Committee Backs Shionogi’s OIC Drug
February 10, 2017
- Post-Marketing Conditions Under “Conditional Early Approval System” Remain Unclear: MHLW Councilor Kazuhiko Mori
February 10, 2017
- 2nd Batch of Sakigake Designation Slated for Spring
February 9, 2017
- Chuikyo Panel to Draw Conclusion by Summer for FY2018 Rollout of Cost-Effective Assessment Scheme
February 9, 2017
- Bill Payers, Doctors in Skirmish over Drug Price Survey for Gap-Year Revisions: Chuikyo
February 9, 2017
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…